KP
Kalyani Patidar
About Kalyani Patidar
Kalyani Patidar has 5 years in corporate governance. Holds Designated Partner and Director roles. Currently with 3 companies, including Neemuch Proteins Llp and Multiverse Proteins Limited. Formerly with 2 companies, such as Morvinandan Petrochem Limited. Engaged in General Business. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Multiverse Proteins Limited
U10402RJ2025PLC109599
|
Director | 12 Dec 2025 | 2025 | Active |
Neemuch Proteins Limited
U10402MP2025PLC079460
|
Director | 06 Oct 2025 | 2025 | Active |
Multiverse Biofuel Limited
U35200MP2025PLC075533
|
Managing Director | 18 Mar 2025 | 2025 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Morvinandan Petrochem Limited
U23209MP2022PLC063681
|
Director | 25 Dec 2024 | 2022 | Active |
Neemuch Proteins Llp
AAV-2039
|
Designated Partner | 22 Dec 2020 | 2020 | Converted And Dissolved |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Kalyani Patidar
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kalyani Patidar
Kalyani Patidar has 5 years in corporate governance. Holds Designated Partner and Director roles. Currently with 3 companies, including Neemuch Proteins Llp and Multiverse Proteins Limited. Formerly with 2 companies, such as Morvinandan Petrochem Limited. Engaged in General Business. Contributes to corporate operations.
Kalyani Patidar is associated with 3 companies as Designated Partner and Director.
Kalyani Patidar has expertise in General Business.
Kalyani Patidar has 5 years in corporate governance.